Comment on: “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”

Farkouh, Raymond; Hall-Murray, Cassandra; Klok, Rogier M.; Hilton, Betsy; Istúriz, Raúl

doi:10.1007/s40121-015-0063-0

Cited by 4 publications

(5 citation statements)

References 29 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, surveillance from PCV10-only countries have failed to show any sustained reduction in 19A invasive disease, as previously discussed. [22][23][24][25] Second, there have not been any conclusive evidence of the lack of PCV13 effectiveness against serotype 3. Finally the assumption that PCV10 has effectiveness against NTHi disease has been widely and repeatedly challenged.…”

Section: Discussionmentioning

confidence: 99%

“…Finally the assumption that PCV10 has effectiveness against NTHi disease has been widely and repeatedly challenged. [22][23][24][26][27][28][29][30][31][32] In addition, of note, by definition, IPD is a severe condition caused by streptococcus pnemoniae, not caused by NTHi. The assumption that PCV10 provided protection against invasive NTHi is not supported by any scientific evidence.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Roberts

Lee

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Keywords: herd effect, incremental cost-effectiveness ratio (ICER), Markov transition-state model, pneumococcal disease, 13-valent pneumococcal conjugate vaccine (PCV13), 10-valent pneumococcal conjugate vaccine (PCV10)Pneumococcal disease causes large morbidity, mortality and health care utilization and medical and non-medical costs, which can all be reduced by effective infant universal routine immunization programs with pneumococcal conjugate vaccines (PCV). We evaluated the clinical and economic benefits of such programs with either 10-or 13-valent PCVs in Malaysia and Hong Kong by using an age-stratified Markov cohort model with many country-specific inputs. The incremental cost per quality-adjusted life year (QALY) was calculated to compare PCV10 or PCV13 against no vaccination and PCV13 against PCV10 over a 10-year birth cohort's vaccination. Both payer and societal perspectives were used. PCV13 had better public health and economic outcomes than a PCV10 program across all scenarios considered. For example, in the base case scenario in Malaysia, PCV13 would reduce more cases of IPD (C2,296), pneumonia (C705,281), and acute otitis media (C376,967) and save more lives (C6,122) than PCV10. Similarly, in Hong Kong, PCV13 would reduce more cases of IPD cases (C529), pneumonia (C172,185), and acute otitis media (C37,727) and save more lives (C2,688) than PCV10. During the same time horizon, PCV13 would gain over 74,000 and 21,600 additional QALYs than PCV10 in Malaysia and Hong Kong, respectively. PCV13 would be cost saving when compared against similar program with PCV10, under both payer and societal perspective in both countries. PCV13 remained a better choice over PCV10 in multiple sensitivity, scenario, and probabilistic analyses. PCV13s broader serotype coverage in its formulation and herd effect compared against PCV10 were important drivers of differences in outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Roberts

Lee

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…effectiveness of the vaccine against serotype 3 ( Table 3). The validity of these assumptions remains highly debated in the literature [8,48] and are described below.…”

Section: Discussionmentioning

confidence: 99%

“…has been contested due to a lack of scientific evidence supporting significant reductions in NTHi-AOM[48,[57][58][59][60][61][62][63]. The Clinical Otitis Media and Pneumonia Study (COMPAS) did not show a significant effect for PCV10-GSK on NTHi-clinically confirmed AOM[63].…”

mentioning

confidence: 99%

A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006-2019)

Wang¹,

Chaiyakunapruk

Zhu

et al. 2021

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Pneumococcal infections can lead to serious invasive diseases such as meningitis, septicaemia and pneumonia, as well as milder but more common illnesses such as sinusitis and otitis media. The World Health Organization (WHO) recommends the inclusion of pneumococcal conjugate vaccines (PCVs) in infant National Immunization Program (NIP) programs worldwide. Decision-makers in Asian countries planning to introduce PCVs in their respective NIP will need a comprehensive evidence of effectiveness of PCVs at the population level and economic evidence including cost-effectiveness. Areas Covered: A systematic literature review (from 1/1/2016 to 10/11/2019) of PCVs in East and Southeast Asia to understand (1) the contributing factors to cost-effectiveness results of PCVs and (2) whether gaps in evidence exist suggesting why the region may have yet to implement full NIPs. Expert Opinion: In East and Southeast Asia, vaccination with PCVs was found to significantly reduce the mortality and morbidity of pneumococcal diseases and was cost-effective compared to no vaccination. Study assumptions, specifically vaccine local acquisition, the inclusion or exclusion of indirect effects (serotype replacement and herd effect), cross-protection, and protection against nontypeable haemophilus influenzae and serotype 3, were the main drivers of cost-effectiveness.

show abstract

“…Allegedly, one of the reasons that a Secretary of Health in our country was summarily dismissed from Office was his controversial decision to procure Pneumonia Conjugate Vaccine (PCV) 10 over PCV13. Existing CEA studies showed that both PCV 10 and PCV13 were cost effective based on GDP per capita with PCV 13 moderately more cost-effective [3][4][5][6]. During this time, information about the protective effect of Protein D carrier unique to PCV10 against H. influenzae disease has yet to be explored.…”

mentioning

confidence: 99%

Usefulness of Cost Effectiveness: Evidence versus Applicability

Vergeire-Dalmacion¹

2015

Pharm Anal Acta

View full text Add to dashboard Cite

All human beings are created equal in terms of right to health and thus qualified to receive the best pharmaceutical option whether for prevention or cure. However, not all humans enjoy the same economic capability to procure their health care. To ensure that health care is inclusive, a responsible government actively assumes the task of procuring the drugs or biological for the health of its population while being mindful of ensuring rational spending and equitable distribution of resources. Cost effectiveness Analysis (CEA) has revolutionized the way doctors in the individual level and policymakers in the level of society should choose the best pharmaceutical intervention by estimating the cost per number of lives saved or cost per disability adjusted life years.

show abstract

Comment on: “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”

Cited by 4 publications

References 29 publications

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006-2019)

Usefulness of Cost Effectiveness: Evidence versus Applicability

Contact Info

Product

Resources

About